



## **MD Anderson Cancer Center is the First Hospital in USA to Order the VMS+ Complete Heart Analysis System**

**Toronto, Ontario, June 6, 2018** – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that MD Anderson Cancer Center in Houston, Texas has ordered the VMS+ complete heart analysis system for use in clinical evaluations of cancer patients. It is well known that chemotherapy agents are cardiotoxic and lead to a significant number of patients acquiring heart dysfunction.

“We are very pleased to have the number-one ranked cancer center in the United States as the first customer,” commented Desmond Hirson, President of Ventripoint. “With our recent market clearance from the FDA, the doctors at MD Anderson will be using the VMS+ to monitor cardiac function in cancer patients.”

According to the Centers for Disease Control and Prevention, there are 23 million people in the USA diagnosed with cancer and these patients visited their physicians 25 million times in 2015. There are over 1,500 cancer centers in the USA, which monitor these existing patients and treat over 1.7 million new patients annually.

The American Heart Association recently put out a scientific statement acknowledging that some breast cancer therapies can damage the heart and healthcare providers should carefully monitor breast cancer treatment effects on the heart. Breast cancer survivors, especially older women, are more likely to die from cardiovascular diseases such as heart failure rather than breast cancer.

Research studies have shown that changes in chamber volumes and function for the right side of the heart are early indicators of the development of heart problems on the left side of the heart in cancer patients and others. The VMS+ provides rapid and accurate assessments for both sides of the heart using conventional 2D ultrasound. These critical measurements are needed to identify patients who require extra cardiac care before, during and after cancer therapy.

### **About MD Anderson Cancer Center**

MD Anderson has been one of the top two cancer centers in the USA for decades. It receives the highest number of research grants from the National Cancer Institute and is the recognized leader in the diagnosis and treatment of cancer. The hospital sees approximately 1.5 million patients a year and performed 575,000 imaging exams in 2017.

### **About Ventripoint Diagnostics Ltd.**

Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and

accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.

For further information please contact:

Dr. George Adams, CEO,

Telephone: (519) 803-6937

Email: [gadams@ventripoint.com](mailto:gadams@ventripoint.com)

### **Forward Looking Statements:**

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at [www.sedar.com](http://www.sedar.com). Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

**Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.**